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The gp120 V3-encoding region of human immunodeficiency virus type 1 (HIV-1) RNA derived from the saliva
and blood plasma of 11 individuals was characterized by heteroduplex tracking assay and sequence analyses.
R5-like viral variants were identified in both fluids of all subjects. X4-like variants were detected in the plasma
and/or saliva of three subjects, indicating that X4-like variants are not excluded from the saliva compartment.
Viral subpopulations were similar in both fluids of most subjects, suggesting that HIV-1 in oral fluids and
blood may stem from a common source. These findings raise the possibility of using saliva as a noninvasive
fluid for evaluating and monitoring viral evolution in infected persons.
Body compartments (e.g., the genital tract, central nervous
system, and breast) are reservoirs of human immunodeficiency
virus type 1 (HIV-1) infection. These sites serve as potential
sources of transmission and rebound virus in individuals whose
viral loads (HIV-1 RNA copies per milliliter) in blood plasma
have been reduced by potent antiretroviral therapy (ART)
(28). Monitoring the HIV-1 burden in viral compartments is
important for assessing transmission risk, disease progression,
and responses to ART.
Mounting evidence suggests that the oral cavity may be a
previously unrecognized viral reservoir. HIV-1 infection can be
acquired through the oral cavity during breast-feeding (19, 31),
oral-genital sex (26), and direct deposition in macaques (27),
despite the low transmission risk associated with saliva (35).
Viral loads exceeding those in matched plasma by up to 102
copies/ml in saliva (33, 34), 103 copies/ml in the tonsils (13),
and 107 copies/ml in lymphoepithelial parotid cyst aspirates
(38) have been recently reported. Discordant viral loads argue
for a distinct oral compartment in which the virus may evolve
independently from blood or other distal compartments.
The heteroduplex tracking assay (HTA) (7) is a powerful
tool for characterizing sequence divergence of viral subpopu-
lations. V3-specific HTA (V3-HTA) rapidly identifies R5-like
and X4-like HIV-1 variants in blood plasma (22) and seminal
plasma (24) based on sequence variability within the gp120
V3-encoding region of env (30). R5 variants utilize CD4 and
the CCR5 chemokine coreceptor for viral entry (1, 6, 8, 9, 10),
typically exhibit a non-syncytium-inducing phenotype in the
MT-2 assay (2), and predominate early in the disease course
(29, 37). X4 variants use the CXCR4 chemokine coreceptor
for virus entry (14), are often syncytium inducing (2), and
may evolve from R5 variants with disease progression (29, 37).
R5X4 variants can use either coreceptor (3). Determinants of
the R5/X4 and non-syncytium-inducing/syncytium-inducing
phenotypes largely reside in the 35-amino-acid V3 domain of
gp120 (21).
We adapted the V3-HTA to characterize the V3-encoding
sequences of saliva-derived HIV-1. Results obtained from V3-
HTA and genotypic analyses of saliva and blood plasma were
compared both within and between infected persons as a first
step in investigating the potential of the oral cavity to serve as
a discrete viral reservoir.
V3-HTA analysis. Blood plasma and whole saliva were col-
lected from 11 adults with clade B HIV-1 infection. Subjects
underwent an oral examination to detect HIV-associated mu-
cosal lesions (11), and medical records were reviewed for im-
munological, viral, and ART data (Table 1). HIV-1 RNA in
saliva was quantitated by Nuclisens assay (Organon Teknika,
Durham, N.C.) (32). Following RNA extraction of patient
samples (4), V3-encoding env regions were amplified by re-
verse transcription-PCR (RT-PCR) as previously described
(22). RT-PCR products (from 1 ml of plasma or 8 ml of saliva)
were annealed to a radiolabeled probe containing the HIV-1
JR-FL V3 sequence, which is nearly identical to the clade B
consensus sequence (18), and heteroduplexes were separated
by nondenaturing polyacrylamide gel electrophoresis (22). RT-
PCR of salivary RNA is typically less efficient than that of
blood plasma (data not shown), and viral loads tend to be
lower in saliva than in plasma (33). Therefore, a larger volume
of saliva-derived amplification products was used in the probe-
annealing step in order to obtain HTA bands of comparable
intensities from paired saliva and blood samples. Mobility ra-
tios were calculated for each visualized heteroduplex band and
used to infer the presence of X4-like (mobility ratio of ,0.91)
and R5-like (mobility ratio of $0.91) genotypes (22).
All subjects had R5-like variants in both body fluids (Fig. 1).
Eight subjects (3004, 3090, 1341, 1351, 9371, 3058, 9411, and
1460) demonstrated only R5-like variants. Heteroduplex mi-
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gration patterns in plasma and saliva were similar for these
subjects, indicating identical or highly related viral subpopula-
tions within both compartments.
X4-like variants (Fig. 1) were identified in RT-PCR products
from subjects 3040, 9208, and 3051. Subject 9208 exhibited
similar HTA patterns in plasma and saliva, suggestive of re-
lated viral subpopulations in the fluids. Subjects 3040 and 3051
had discordant HTA patterns; bands present in either plasma
(3040) or saliva (3051) were not detected in the other fluid
sample (Fig. 1), indicating the existence of distinct viral sub-
populations in these fluids. To obtain HTA bands of equal
intensity, eight times as much of the PCR products derived
from saliva samples was loaded onto HTA gels compared to
PCR products derived from blood samples. It is possible that
the unique band in the blood of subject 3040 was present in the
saliva but was not amplified to a detectable level due to fewer
viral RNA copies in the saliva than in the blood (4.23 log10
versus 5.20 log10 [Table 1]) or less efficient RT of saliva-derived
RNA (data not shown). By the same token, however, the X4-
like band in the saliva of subject 3051 was not detected in the
blood despite the probable sampling of more viral templates in
blood. Because this unique heteroduplex band was detected
consistently from two independent PCRs, we are confident of
its presence in the saliva of subject 3051. The faint, slowly
migrating bands in plasma of patients 3058 and 9411 are
primer artifacts that are present in all lanes upon darker ex-
posure of the autoradiogram (data not shown).
Differences in ART responses may contribute to the dynam-
ics of viral replication within the blood and the oral cavity, as
has been shown in blood and the genital tract (12, 16, 39).
Thus, discordant V3-HTA banding patterns observed in sam-
ples from subjects 3040 (plasma) and 3051 (saliva) may be due
to sample lag time, i.e., the number of days between blood and
saliva collections (Table 1). These unique X4-like bands may
TABLE 1. Characteristics of study participantsa










RNA copies/ml Hemoglobin content
in salivad (mg/dl)
Plasma Saliva
3040 45 M W 8 Asymptomatic 205 None None 5.20 4.23 ,10
3004 31 M W 70 Asymptomatic 358 3TC None 4.10 3.59 10–50
3090 39 M W 0 Symptomatic 270 ZDU HLP 4.67 3.49 .200
1341 40 M W 9 AIDS 288 ZDU, 3TC None 4.14 3.85 50–200
9208 31 F B 0 AIDS 308 ZDU, 3TC, IND Candidiasis, SGD 4.31 3.45 .200
3051 31 F W 48 Symptomatic 400 None None 4.91 5.90 ND
1351 27 M W 87 Asymptomatic 576 None None 4.78 5.88 .200
9371 35 M W 16 Asymptomatic 351 None None 4.99 5.76 10–50
3058 34 M B 0 AIDS 169 ZDU, 3TC None 5.12 4.87 50–200
9411 50 M B 87 AIDS 4 3TC, NEV, IND None 4.00 4.26 50–200
1460 29 M B 0 Asymptomatic 229 None None 4.44 3.83 .200
a Abbreviations: M, male; F, female; W, Caucasian (non-Hispanic); B, African-American; 3TC, lamivudine; ZDU, zidovudine; IND, indinavir; NEV, nevirapine;
SGD, HIV-associated salivary gland disease; HLP, hairy leukoplakia; ND, not done.
b Number of days between plasma and saliva collections.
c Based on the Centers for Disease Control’s revised classification (5).
d A 10-mg/dl hemoglobin level corresponds to approximately 60 red blood cells.
FIG. 1. V3-HTA analysis of the HIV-1 V3 region in plasma and saliva. Viral RNA was isolated from the plasma (P) and saliva (S) of 11 infected
individuals, and the gp120 V3-encoding region was amplified by RT-PCR. Amplification products were annealed to a radiolabeled clade B
consensus R5-like sequence probe. Heteroduplexes were separated on a 12% polyacrylamide gel and analyzed by autoradiography. X4-like bands
are indicated by arrows. Bands marked by double arrows are unique to a body fluid.
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have arisen from rapid viral evolution in the compartments
during the 8 and 48 days, respectively, between sample collec-
tions. HTA patterns for all samples were consistent upon re-
peat PCR amplification and HTA analysis (data not shown).
Genotypic analysis. DNA sequences of visualized V3-HTA
heteroduplexes were determined by direct sequencing of RT-
PCR products (single discrete bands) or cloning prior to se-
quencing (single wide bands and multiple discrete bands). The
predicted amino acid sequences were aligned with the probe
V3 sequence and classified as X4-like or R5-like using amino
acid sequence criteria (20) (Table 2). With three exceptions, all
X4-like genotypes corresponded to a mobility ratio of ,0.91
whereas a mobility ratio of $0.91 was consistent with an R5-
like genotype, verifying previous findings (22). The slowly mi-
grating heteroduplex band identified in saliva-derived products
of subject 3051 (Fig. 1) contained a leucine insertion following
amino acid position 15 in the V3 loop (Table 2). Although the
sequence was R5-like based on genotypic criteria (20), the
insertion shifted the band above the X4-like-defining mobility
ratio, as has been shown with other patient-derived sequences
containing insertions and deletions (22). Sequence data repre-
senting X4-like heteroduplex bands from plasma and saliva
(0.69 mobility ratio) of patient 3040 indicate an arginine-to-
tryptophan substitution in 2 of the 17 sequences (Table 2).
Because the change does not involve a basic substitution at
position 24 that defines X4-like viruses (20), these sequences
are therefore classified as R5-like. The nucleotide sequence of
the unique plasma-derived HTA band (0.88 mobility ratio)
from patient 3040 differed by only a single noncoding change
compared to the sequence of the most closely related R5-like
product (0.93 mobility ratio) from the plasma of that patient
(Table 2). Compared to the probe sequence, this single muta-
tion clustered with other single mutations to produce a more
slowly migrating heteroduplex that is likely a member of the
same R5 population rather than a unique viral variant (Ta-
ble 2).
The nucleotide sequence of this unique band from patient
3040 was identified only once in a screening of over 100 clones
from multiple RT-PCR products. Also, screening of more than
200 clones from several RT-PCR products yielded a single
sequence representing the X4-like heteroduplex band derived
from the saliva of this patient (Table 2). Therefore, viral vari-
TABLE 2. Analysis of patient-derived V3 sequences





1 11 13 24 25 35
None (probec) C T R P N N N T R KS I H I G . P G R A F Y T T G E I I G D I R Q A H C R5
1341 6 P – – – – G – – – – – – – P M – . – – K – V – A – – D – – – – – – – – – – R5-like 0.96
1 P – – – – G – – – – – – – P M – . – – K – – – A – – D – – – – – – – – – – R5-like 0.96
1 P – – – – G – – – – – – – – M – . – – K – – – A – – D – – – – – – – – – – R5-like 0.96
1 P – – – – G – – – – R – – – M – . – – K – – – A – – D – – – – – – – – – – R5-like 0.96
1 P – – – – G – – – – R – – – M – . – – – – – – A – – D – – – – – – – – – – R5-like 0.96
1 P – – – – G – – – – R – – – M – . – – – – – – A – – D – – – – – K – – – – R5-like 0.96
4 P, 2 S – – – – G – – – – – – – – – – . – – K – – – A – – D – – – – – – – – – – R5-like 0.96
3040 1 S – – – – – – – – – R – – – M – . – – K – – – – – – D – – – – – – – – – – R5-like 0.93
1 S – – – – – – – – – R – – P M – . – – K – – – A – – D – – – N – – – – – – R5-like 0.93
2 P – – – – – – – – – – G – N – – . – – – – W – A – – D – – – – – – – – – – R5-like 0.93
1 P – – – – – – – – – – G – N – – . – – – – C – A – S D – – – – – – – – – – R5-like 0.93
6 P, 1 S – – – – – – – – – – G – N – – . – – – – W – A – S D – – – – – – – – – – R5-like 0.93
1 P – – – – – I – – – – – – N – – . – – K – L – A – S D – – – – – – – – – – R5-like 0.93
1 P – – – – – – – – – – – – N – – . – – – – W – A – – D – – – – – – – – – – R5-like 0.93
1 P – – – – – – – – – – G – N – – . – – – – W – A – S D – – – – – – – – – – R5-like 0.88
1 P, 1 S – – – – – – – – – R – – Q – – . – – – – W H – – W . – – – – – – – – – – R5-like 0.69
7 P – – – – – – – – – R – – Q – – . – – – – W H – – R . – – – – – – – – – – X4-like 0.69
8 P – – – – – – – – – R – – Q – – . – – – – W H – – R . T – – – – – – – – – X4-like 0.69
9208 1 P, 1 S – – – – – – – – – R – – – M – . – – K – – – – – – D – – – – – – – – – – R5-like 0.95
1 S – – – – – – – – – R – – – M – . – – K – – – – – – N – – – – – – – – – – R5-like 0.95
1 S – – – – – – – – – G – – P M – . – – K – – – A S – D – – – N – V – – – – R5-like 0.95
1 P, 1 S – – – – Y – H – – – – – R – – . – – – – – – – – R N V – – – – – – – – – X4-like 0.54
1 P, 1 S – – – – Y – H – – – – – – – – . – – – – – – – – R N V – – – – – – – – – X4-like 0.54
1 S – – – – – – H – – – – – – – – . – – – – – – – – R N V – – – – – – – – – X4-like 0.54
1 S – – – – – – H – T R R – – – – . – – – – – – – – – N V – – – – – – – – – X4-like 0.54
1351 2 P – – – – – – – – – – – – – – – . – – – T – – A – – D – – – N – – – – – – R5-like 0.94
2 S – – – – – – – – – – – – – – – . – – – T – – A – – D – – – – – – – – – – R5-like 0.94
1 S – – – – H R T – – – – – – – – . – – – T – – A – – D – L – – – – – – – – R5-like 0.94
3051 2 P, 2 S – – – – – – – – – R – L N – – . – – – – – – – – – Q – – – – – – – – – – R5-like 0.97
1 S – – – – G – – – – R – – N – – L – – G – – – – – – Q – – – – – – – – – – R5-like 0.73
3058 2 P – – – – – – – – – R – – S – – . – – – – – F – – – – V – – N – – – – – – R5-like 0.97
1 S – – – – S – – – – R – – S – – . – – – – – F – – – – V – – N – – – – – – R5-like 0.97
3090 2 P – – – – – – – – – – – – – – – . – – S – – – – – – – – – – – – – – – – – R5-like 0.97
6 S – – – – – – – – – – – – – – – . – – S – – – – – – A – – – – – – – – – – R5-like 0.97
1460 2 P, 2 S – – – – – – – – – – G – – – – . – – – – – – – – – Q – – – – – – – – – – R5-like 0.97
3004 2 P, 2 S – – – – F – H – – – – – N – – . – – – – – – A – – – – – – – – – – – – – R5-like 0.96
9371 2 P, 2 S – – – – – – – – – – – – – – – . – – – – – – A – – – – – – – – – – – – – R5-like 0.98
9411 2 P, 2 S – – – – – – – – – – G – P – – . – – – – – – A – – – – – – – – – – – – – R5-like 0.98
a Number of clones from plasma (P) or saliva (S) with the predicted amino acid sequence.
b R5-like or X4-like genotype determined by presence of basic amino acids at the bold positions.
c Residues overlapping PCR amplification primers are underlined in the probe amino acid sequence.
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ants corresponding to these bands likely represent a very small
proportion of the total viral populations in this patient.
Comparison of patient-derived sequences revealed that no
sequence was represented in more than one patient, and in a
neighbor-joining tree, sequences clustered within but not be-
tween patients (data not shown). Based on concordance be-
tween V3-HTA and DNA sequence data, most subjects har-
bored genetically similar virus populations in both fluids.
Contaminating blood in saliva. HIV-1 may arise from bleed-
ing oral tissues. To determine whether contaminating blood
influenced study findings, hemoglobin content was estimated in
saliva using a quantitative test strip method (17, 33). Neither
the presence nor the quantity of blood in saliva was predictive
of an R5-like/X4-like genotype, as R5-like variants were iden-
tified in the saliva of all patients despite highly variable hemo-
globin levels and X4-like variants were present in subjects with
unquantifiable (3040) as well as high (9208) hemoglobin levels
(Table 1). Also, a high HIV-1 RNA level in hemoglobin-free
saliva (subject 3040) suggests that a nonblood source of virus
exists in the oral cavity of this subject. Potential oral sources of
the virus include the tonsils (13, 15, 25), mononuclear cells
trafficking into the oral cavity (23), the salivary glands (38, 40),
and gingival crevicular fluid (serum transudate bathing gingival
tissues) (36). Additional study is needed to assess the contri-
butions of these sources to oral viral shedding and the poten-
tial for the oral cavity to serve as a reservoir of residual infec-
tion following ART.
Conclusions. To develop effective ART regimens, all ana-
tomical sources of HIV-1 infection must be identified and
techniques must be developed to monitor viral loads within the
affected sites. This study identified oral secretions as a substan-
tial source of viral RNA and raises the possibility of using
saliva as a noninvasive body fluid for evaluating and monitor-
ing viral evolution and ART intervention. We also documented
one case of discordant HIV-1 subpopulations in peripheral
blood and the oral cavity (subject 3051). The latter finding
suggests that selected individuals (e.g., subject 3051) may har-
bor different viral populations in the blood and oral fluids, as
has been widely documented for blood and other body fluids
(28), and warrants further analysis of other viral gene-encoding
regions in paired fluids from a larger cohort.
Nucleotide sequence accession numbers. Sequences have
been submitted to GenBank and have been given accession
numbers AF362846 through AF362885.
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